NeOnc Technologies Holdings, Inc. NTHI PHARMA
Company Overview
NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary brain cancers. The company was formerly known as NAS-ONC, Inc. and changed its name to NeOnc Technologies Holdings, Inc. in 2009. The company was incorporated in 2005 and is headquartered in Calabasas, California.
Why Investors Should Care
Revenue has grown at a 26.0% CAGR over the past five years.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $39.99K (-51.8% YoY); net profit $-62.15M.
- Trailing 12 Months Year-on-year growth — revenue -51.8%.
- 5-Year Trend Long-term compounding — revenue CAGR 26.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 25.98% |
| 1 Year: | -51.82% |
Stock Price Performance
| 1 Year: | -23.50% |
| 6 Months: | -58.17% |
| 3 Months: | -9.35% |
| 1 Month: | +16.29% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)45.12 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 26.0% over 5 years.
- Generates positive free cash flow.
CONS
- Trading 66.3% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | NTHI NeOnc Technologies Holdings, Inc. PHARMA | 4.07 | -1.92 | $117.24M | 0.00% | - | - | 25.98% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 43.00K | 20.00K | - | - | 39.99K | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | 31.94M | 5.71M | 6.93M | 13.63M | 7.01M | - |
| Operating Income | -1.55M | -1.28M | -2.20M | - | -31.90M | -5.71M | -6.93M | -13.63M | -7.01M | -14.07M |
| EBITDA | - | - | - | - | -32.02M | -5.61M | -7.73M | -14.25M | -7.81M | - |
| Interest Expense | - | - | - | - | 308.92K | 48.75K | 869.82K | 1.28M | 982.62K | - |
| Pretax Income | - | - | - | - | -32.33M | -5.68M | -8.62M | -15.52M | -8.82M | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - |
| Net Income | -2.94M | -4.52M | -2.18M | - | -32.33M | -5.68M | -8.62M | -15.52M | -8.82M | -14.24M |
| Diluted EPS | -0.18 | -0.27 | -0.12 | - | -1.78 | -0.30 | -0.45 | - | -0.38 | -0.58 |
| R&D Expense | 614.52K | 394.48K | 956.73K | - | 998.22K | 677.33K | 715.04K | - | 1.29M | 2.65M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 20.00K | 70.46K | 83.00K | 39.99K |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | - | 2.86M | 8.17M | 7.23M | 58.21M |
| Operating Income | - | -2.84M | -8.10M | -7.14M | -58.17M |
| EBITDA | - | -2.85M | -12.20M | -9.10M | -59.61M |
| Interest Expense | - | 200.15K | 2.72M | 2.56M | 2.50M |
| Pretax Income | - | -3.05M | -14.92M | -11.90M | -62.15M |
| Tax Provision | - | - | - | - | - |
| Net Income | - | -3.05M | -14.92M | -11.90M | -62.15M |
| Diluted EPS | - | -0.16 | -0.80 | -0.63 | -3.20 |
| R&D Expense | - | - | - | 3.05M | 3.64M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 728.68K | 1.27M | 3.42M | 2.82M |
| Current Assets | - | 728.68K | 1.27M | 2.20M | 1.39M |
| Cash & Equivalents | - | 633.30K | 31.86K | 64.89K | 58.73K |
| Inventory | - | - | - | - | - |
| Receivables | - | - | - | - | - |
| Total Liabilities | - | 2.30M | 15.25M | 8.92M | 20.33M |
| Current Liabilities | - | 2.30M | 15.25M | 8.92M | 20.04M |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | 50.00K | 6.61M | 24.72K | 6.31M |
| Total Equity | - | -1.58M | -13.99M | -5.50M | -17.51M |
| Shares Outstanding | - | 18.75M | 18.75M | 18.75M | 21.99M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -881.74K | -1.88M | -4.21M | -20.36M |
| Investing Cash Flow | - | - | - | 0 | -500.00K |
| Financing Cash Flow | - | 1.49M | 1.28M | 4.25M | 20.86M |
| Capital Expenditure | - | - | - | - | -500.00K |
| Free Cash Flow | - | -881.74K | -1.88M | -4.21M | -20.86M |
| Net Change in Cash | - | 608.26K | -601.44K | 33.03K | -6.16K |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | -14,188.0% | -11,492.2% | -8,605.4% | -145,459.4% |
| Net Margin % | - | -15,233.8% | -21,176.0% | -14,335.5% | -155,404.4% |
| ROE % | - | 193.4% | 106.7% | 216.1% | 355.0% |
| ROCE % | - | 180.1% | 57.9% | 129.7% | 337.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Cinctive Capital Management LP | 6.14% | 1.61M | $5.24M |
| 2 | Vanguard Capital Management LLC | 1.92% | 504.17K | $1.64M |
| 3 | Bank of America Corporation | 0.86% | 224.41K | $731.58K |
| 4 | Westmount Partners, LLC | 0.75% | 197.18K | $642.80K |
| 5 | Blackrock Inc. | 0.69% | 179.85K | $586.31K |
| 6 | Geode Capital Management, LLC | 0.63% | 166.12K | $541.55K |
| 7 | Vanguard Fiduciary Trust Co | 0.35% | 91.48K | $298.22K |
| 8 | State Street Corporation | 0.16% | 43.17K | $140.73K |
| 9 | Northern Trust Corporation | 0.14% | 35.87K | $116.94K |
| 10 | Global Retirement Partners, LLC | 0.11% | 27.79K | $90.59K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for NTHI
NeOnc Technologies Holdings Inc (NTHI) (Q2 2026) Earnings Call Highlights: First Annual Meeting ...
All stockholder proposals approved, including director elections and equity incentive plan expansion, with no financial or operational updates provided.
Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NTHI) 2Q26
Dallas, Texas--(Newsfile Corp. - August 13, 2026) - NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI). Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI). 2Q26 meaningfully improves the clinical s…
NeOnc Technologies shares jump after positive Phase 2a glioma results
NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) shares climbed 11.
NeOnc Technologies to Host Investor Conference Call to Discuss Topline Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma
NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) ("NeOnc” or the "Company”), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced that it will host an …
NeOnc Technologies Appoints Strategy and Finance Executive Nasim Shomali to its Board of Directors
NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced the appointment of Na…
NeOnc Receives FDA Written Feedback on NEO212 CMC Development and Capsule-to-Tablet Transition
FDA feedback provides detailed manufacturing and formulation requirements for continued late-stage development of NEO212CALABASAS, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) (“NeOnc” or the “C…
NTHI — Frequently Asked Questions
What is the current share price of NeOnc Technologies Holdings, Inc. (NTHI)?
As of 2026-09-19 21:16 PDT, NeOnc Technologies Holdings, Inc. (NTHI) trades at $4.07 on NasdaqGM. Its 52-week range is $3.21 to $12.09.
What is the market capitalisation of NTHI?
NeOnc Technologies Holdings, Inc. (NTHI) has a market capitalisation of $117.24M on NasdaqGM.
What is the P/E ratio of NTHI?
NTHI trades at a trailing price-to-earnings (P/E) ratio of -1.92. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is -3.74.
Is NTHI a good stock to buy?
This page provides a data-driven analysis of NeOnc Technologies Holdings, Inc. (NTHI), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.